Inion appoints Paul Garvey as a Non-executive Director

Tampere, Finland and Takeley, UK. 22nd April 2005.

Inion (LSE: IIN), a rapidly growing company focused on the development of novel biodegradable medical implants, is pleased to announce the appointment of Mr Paul Garvey to the Board of Directors as a non-executive director with effect from 21st April 2005.

Also with effect from 21st April, Mr Staffan Lindstrand resigns from his position as a Non-executive Director. Mr Lindstrand has served on the Inion board since March 2003.

Mr Garvey (age 52) is currently the group Finance Director of diagnostics company Axis-Shield plc (LSE: ASD), which he joined in 2000. He has previously served as Managing Director and Finance Director in a number of businesses in the UK and Ireland since 1983.

Dr Auvo Kaikkonen, CEO of Inion, said, "I am delighted to welcome Paul to our Board of Directors. His excellent track record and skills will strengthen the Board and complement the skills already present. We are looking forward eagerly to the valuable contribution that he will make to our growing business. On behalf of Inion, I would also like to express my thanks to Staffan for all he has contributed to the company over the past two years."

Inion can advise that there are no further details relating to the appointment of Paul Garvey, which it is obliged to disclose under paragraph 6.F.2. (b-g) of the Listing Rules of the UK Listing Authority.

For further information, please contact:

Inion Oy

Dr Auvo Kaikkonen, Chief Executive Officer +44 358 3 230 6600

Citigate Dewe Rogerson +44 (0)20 7638 9571

Mark Swallow / David Dible

About Inion

Inion Oy is a Finnish company that specialises in the development of biodegradable medical implants. Inion’s core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes that are used to enhance the healing of skeletal injuries (bone and soft tissue), such as those caused by trauma or by reconstructive surgery. Inion’s implants are made from its proprietary OPTIMA™ family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation.

Inion has developed and launched products in four strategic business areas – cranio-maxillofacial surgery, orthopaedic trauma, sports medicine and dental surgery – in more than 40 countries worldwide, and has a number of international distribution agreements in place, with among others Stryker Corporation and Aesculap (part of B.Braun).

Inion was incorporated in early 2000 by an international team of experts in biodegradable materials and their clinical applications, and listed on the Official List of the UK Listing Authority in December 2004 (LSE: IIN). The Company’s has corporate headquarters in the UK, R&D and production facilities in Tampere, Finland, and a US office in Oklahoma City, OK.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion’s funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.